At a glance
RSV Monoclonal Antibody Receipt and Intent for Infants
Monthly estimates of infant protection against RSV by maternal RSV vaccination or infant receipt of RSV monoclonal antibody (nirsevimab or clesrovimab), as well as intent for RSV monoclonal antibody receipt, were calculated using data from the National Immunization Surveys (NIS)-Fall Respiratory Virus Module (NIS-FRVM). The NIS-FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. Data were reported by adult females aged 18–49 years with infants under the age of 8 months during the RSV season (born since April 1, 2025). All estimates are based upon parent-reported receipt of RSV monoclonal antibody.
- Figure 4. Infant Protection Against RSV by Maternal RSV Vaccination* or Receipt of RSV Monoclonal Antibody,† and Intent for RSV Monoclonal Antibody Receipt,‡ Reported by Females Aged 18–49 Years Who Have an Infant <8 Months During the RSV Season (Born Since April 1, 2025), by Month of Interview, United States§,±. Data Source: National Immunization Survey-Fall Respiratory Virus Module.
Note: In past seasons NIS-FRVM was referred to as the NIS-Adult COVID Module (NIS-ACM).
Confidence Intervals (CIs) describe the level of uncertainty around an estimate because a sample was taken. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% confidence interval, if the sampling method is repeated many times, the true value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
Estimates from the NIS-FRVM may differ from estimates based on other data sources, and in addition to random error associated with taking a sample, are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self-reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
*Receipt of RSV vaccination during pregnancy was assessed by the NIS-FRVM questionnaire among females 18–49 years who reported having an infant born since October 1, 2025. For infants born April 1, 2025, through September 30, 2025, maternal RSV vaccination was not assessed, and these infants were assumed to be protected against RSV only if infant was reported to have received RSV monoclonal antibody (nirsevimab or clesrovimab). The estimates of receipt of RSV vaccination during pregnancy for infants born since April 1, 2025 are not an assessment of maternal RSV vaccination coverage among pregnant persons eligible for vaccination as shown with the Vaccine Safety Datalink, as they are based on all infants eligible for RSV monoclonal antibody or maternal vaccination rather than eligible pregnancies (RSV Vaccine Guidance for Pregnant Women).
†Estimates of RSV monoclonal antibody (nirsevimab or clesrovimab) receipt by infants born since April 1, 2025, include those who were born shortly before or are entering their first RSV season and do not account for the mother's RSV vaccination status during pregnancy (Healthcare Providers: RSV Immunization for Children 19 Months and Younger | CDC).
‡Intent for RSV monoclonal antibody receipt is assessed among infants who had not received RSV monoclonal antibody and whose mother did not receive RSV vaccination during pregnancy.
§National estimates include 50 states, Washington D.C., Puerto Rico, and the U.S. Virgin Islands (included in 2021, 2023, and 2025 calendar years).
±Estimates are based on interviews conducted during Sunday through Saturday weeks assigned to the monthly analytic period, which may include some dates in the month before or after the specified analytic month. Unlike the weekly RSV vaccination coverage estimates, they are not cumulative estimates based on all interviews conducted to date.